{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:02:03Z","timestamp":1792836123045,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Resistant hypertension is highly prevalent among individuals with chronic kidney disease (CKD) and is closely associated with accelerated decline of renal function and increased cardiovascular morbidity and mortality.<\/jats:p>\n                  <jats:p>Recent clinical guidelines have established clearer blood pressure (BP) targets for this population, generally recommending office BP values below 140\/90 mmHg, with a more stringent target of &amp;lt;130\/80 mmHg for patients with albuminuria, diabetes, high cardiovascular risk, or transplant. Conversely, systolic pressure &amp;lt;120 mmHg is not advised due to concerns regarding renal hypoperfusion and associated adverse cardiovascular outcomes.<\/jats:p>\n                  <jats:p>Initial treatment involves an optimized triple therapy regimen with a renin\u2013angiotensin system blocker, a calcium channel blocker, and a diuretic, with the addition of beta-blockers in patients with cardiac comorbidities. Patients with poorly controlled BP require a fourth agent. Spironolactone remains a preferred option when the estimated glomerular filtration rate is \u226530 ml\/min\/1.73 m\u00b2, but long-term adherence is poor. Chlorthalidone is suitable in more advanced CKD, particularly combined with loop diuretics. Centrally sympatholytic agents represent a valuable alternative.<\/jats:p>\n                  <jats:p>Sodium-glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like peptide 1 receptor agonists have demonstrated both antihypertensive effects and clear renal and cardiovascular benefits. Dual endothelin receptor antagonist may offer an additional option in patients with resistant hypertension. Renal denervation represents another promising approach. In selected cases of atherosclerotic renovascular disease with high-grade stenosis and clinical risk features, revascularization may provide benefit.<\/jats:p>\n                  <jats:p>Collectively, these developments support a more individualized and evidence-based approach to managing resistant hypertension in CKD.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf285","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T11:54:12Z","timestamp":1758196452000},"page":"ii10-ii16","source":"Crossref","is-referenced-by-count":5,"title":["2025 Update on resistant hypertension in CKD: where do we stand and where do we go?"],"prefix":"10.1093","volume":"18","author":[{"given":"Roland E","family":"Schmieder","sequence":"first","affiliation":[{"name":"University Hospital Erlangen, Friedrich Alexander University Erlangen\/N\u00fcrnberg Department of Nephrology and Hypertension, , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"2025121209163996300_bib1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/HJH.0000000000000023","article-title":"Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study","volume":"32","author":"Tsioufis","year":"2014","journal-title":"J Hypertens"},{"key":"2025121209163996300_bib2","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2025121209163996300_bib3","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2025121209163996300_bib4","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1093\/ndt\/gfad095","article-title":"Atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH)","volume":"38","author":"Sarafidis","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163996300_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"key":"2025121209163996300_bib6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/HJH.0000000000001874","article-title":"Unattended automated office vs. ambulatory blood pressure in people with high cardiovascular risk: implications for understanding the SPRINT results","volume":"37","author":"Kjeldsen","year":"2019","journal-title":"J Hypertens"},{"key":"2025121209163996300_bib7","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/1740774514537404","article-title":"The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)","volume":"11","author":"Ambrosius","year":"2014","journal-title":"Clinical Trials"},{"key":"2025121209163996300_bib8","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"2025121209163996300_bib9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/HYPERTENSIONAHA.116.08076","article-title":"Effect of intensive versus standard clinic-based hypertension management on ambulatory blood pressure: results from the SPRINT (Systolic Blood Pressure Intervention Trial) ambulatory blood pressure study","volume":"69","author":"Drawz","year":"2017","journal-title":"Hypertension"},{"key":"2025121209163996300_bib10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/ndt\/gfae041","article-title":"A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) guidelines for the management of arterial hypertension","volume":"39","author":"Sarafidis","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163996300_bib11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1681\/ASN.0000000000000072","article-title":"Intensive BP control in patients with CKD and risk for adverse outcomes","volume":"34","author":"Ku","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163996300_bib12","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1056\/NEJMoa2212270","article-title":"Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events","volume":"387","author":"Ishani","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121209163996300_bib13","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121209163996300_bib14","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2025121209163996300_bib15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","article-title":"Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (resistant hypertension optimal treatment)","volume":"71","author":"Krieger","year":"2018","journal-title":"Hypertension"},{"key":"2025121209163996300_bib16","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"2025121209163996300_bib17","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"2025121209163996300_bib18","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"2025121209163996300_bib19","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025121209163996300_bib20","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"2025121209163996300_bib21","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2025121209163996300_bib22","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY subgroup analysis","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025121209163996300_bib23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025121209163996300_bib24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2025121209163996300_bib25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"2025121209163996300_bib26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jama.2025.6681","article-title":"Add-on treatment with zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial","volume":"334","author":"Desai","year":"2025","journal-title":"JAMA"},{"key":"2025121209163996300_bib27","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.124.069709","article-title":"Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis","volume":"150","author":"Vukadinovi\u0107","year":"2024","journal-title":"Circulation"},{"key":"2025121209163996300_bib28","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1161\/HYP.0000000000000240","article-title":"Renal denervation for the treatment of hypertension: a scientific statement from the American Heart Association","volume":"81","author":"Cluett","year":"2024","journal-title":"Hypertension"},{"key":"2025121209163996300_bib29","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/ndt\/gfac189","article-title":"Renal denervation in patients with chronic kidney disease: current evidence and future perspectives","volume":"38","author":"Schmieder","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025121209163996300_bib30","doi-asserted-by":"publisher","first-page":"B159","DOI":"10.1016\/j.jacc.2024.09.565","article-title":"TCT-486 ultrasound-based renal denervation reduces blood pressure in patients with chronic kidney disease: results of a multicenter prospective randomized sham-controlled blinded investigator initiated trial","volume":"84","author":"Schmieder","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025121209163996300_bib31","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/ndt\/gfab154","article-title":"Renal denervation in patients with versus without chronic kidney disease: results from the global SYMPLICITY registry with follow-up data of 3 years","volume":"37","author":"Ott","year":"2022","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf285\/64415913\/sfaf285.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/Supplement_2\/ii10\/64415913\/sfaf285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/Supplement_2\/ii10\/64415913\/sfaf285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:16:43Z","timestamp":1765549003000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/18\/Supplement_2\/ii10\/8266526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":31,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2025,12,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf285","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,26]]}}}